Biogen (NASDAQ:BIIB) reported upbeat earnings for the first quarter on Wednesday.
The company posted quarterly earnings of $3.57 per share which beat the analyst consensus estimate of $3.01 per share. The company reported quarterly sales of $2.478 billion which beat the analyst consensus estimate of $2.255 billion.
Biogen cut its FY2026 adjusted EPS guidance from $15.25-$16.25 to $14.25-$15.25.
Biogen shares fell 1.3% to trade at $191.84 on Thursday.
These analysts made changes to their price targets on Biogen following earnings announcement.
- Wedbush analyst …